Skin health and disease最新文献

{"title":"SHD reviewers January 2024-December 2024.","authors":"","doi":"10.1093/skinhd/vzaf035","DOIUrl":"https://doi.org/10.1093/skinhd/vzaf035","url":null,"abstract":"","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"167-169"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A red nodule in the umbilicus of an older man.","authors":"Sarah Winter, Sally Ashton, Daniel Housa, Avad Mughal","doi":"10.1093/skinhd/vzaf018","DOIUrl":"10.1093/skinhd/vzaf018","url":null,"abstract":"<p><p>This case report describes an interesting example of a syringocystadenoma papilliferum lesion presenting in a 72-year-old man. He presented with a 10-month history of a red nodule in his umbilicus with unexplained weight loss and reduced appetite. The patient had a background of chronic obstructive pulmonary disease, treated prostate cancer and pemphigus vulgaris that had previously been treated with azathioprine. The nodule would occasionally bleed with trauma, but there were otherwise no associated symptoms. Physical examination revealed a 12 × 12 mm firm red nodule within the umbilicus with some creamy exudate overlying it. Given the clinical presentation, differentials at the time included Sister Mary Joseph nodule, amelanotic melanoma and pyogenic granuloma. A shave biopsy was arranged to help diagnose the nodule and further investigations including computed tomography (CT) and colonoscopy were undertaken. CT and colonoscopy did not indicate any sinister pathology. Histopathological findings demonstrated mildly cystic invaginations arising from a papillomatous epidermis that were lined by rows of cuboidal-to-columnar epithelial cells, with oval nuclei and a pale eosinophilic cytoplasm with squamous metaplasia. The stroma contained a dense mononuclear infiltrate, which was comprised predominantly of plasma cells and lymphocytes. The histopathological findings were of syringocystadenoma papilliferum. This report discusses the clinical and histopathologicial presentation of syringocystadenoma papilliferum and the investigations and management to consider with this diagnosis. We also discuss the various differentials that should be considered for a red nodule in the umbilicus.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"158-160"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia.","authors":"Faizan Fazal, Bilal Haider Malik, Haris Mumtaz Malik, Beenish Sabir, Haris Mustafa, Mushood Ahmed, Areesha Abid, Maham Leeza Adil, Umar Shafi, Muhammad Saad","doi":"10.1093/skinhd/vzaf009","DOIUrl":"10.1093/skinhd/vzaf009","url":null,"abstract":"<p><p>Androgenetic alopecia (AGA) is a hair disorder seen in both sexes. Its aetiology is multifactorial. Treating AGA has always been a challenge for dermatologists. Only a few drugs such as topical minoxidil and finasteride are U.S. Food and Drug Administration-approved for treating AGA. Thus, looking for new and more effective treatment options for AGA is imperative. This review was conducted to compare the efficacy of oral with topical minoxidil in treating AGA. Only clinical trials that compared oral with topical minoxidil in treating AGA were included in this review. PubMed, Cochrane, Scopus and ClinicalTrials.gov were searched. A total of 2063 studies were retrieved from the databases. Four studies met the inclusion criteria and were included in this systematic review. Outcomes such as hair density, terminal hair density, hair count, global photographic assessment and negative hair pull were studied in this review. The results showed that there was no significant difference between oral and topical minoxidil in terms of improving the hair density of patients with AGA (overall mean difference 0.95, 95% confidence interval -24.98 to 26.87). Two studies showed that the mean difference in terminal hair density was greater in patients treated with oral minoxidil, but there was no significant difference between the two treatments in terms of improving terminal hair density. The efficacy of oral minoxidil is comparable to that of topical minoxidil in terms of improving hair density and terminal hair density in patients with AGA. Oral minoxidil can be used as an adjunct or as a second-line treatment option for AGA.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"95-101"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous small vessel vasculitis in the COVID-19 era: a systematic review.","authors":"Katherine Oakley Olson, Siddharth Patel, Prutha Pathak, Lucy Page Kelly, Mc Anto Antony, Mrudula Thiriveedi","doi":"10.1093/skinhd/vzaf004","DOIUrl":"10.1093/skinhd/vzaf004","url":null,"abstract":"<p><strong>Background: </strong>Dermatological adverse effects may occur after COVID-19 infection or vaccine administration. Since the beginning of the pandemic, several case reports and systematic reviews have been published on vasculitis associated with both COVID-19 infection and vaccination. Fever, malaise, urticaria, and rash are common symptoms of COVID-19. These symptoms can also occur as adverse reactions to COVID-19 vaccines. However, the occurrence of serious autoimmune reactions due to COVID-19 infection or its vaccine is rare. Cutaneous small vessel vasculitis (CSVV) is an autoimmune disorder that manifests with palpable purpura and petechiae involving the extremities. It results from neutrophilic inflammation within and around dermal vessels and is usually self-limited.</p><p><strong>Objective: </strong>We provide a thorough systematic review on CSVV occurring in the COVID-19 era.</p><p><strong>Methods: </strong>We followed the PRISMA 2020 checklist for systematic review, searching PubMed, Google Scholar, Cochrane, and Embase. We included case reports, case series, correspondence articles, and letters to the editor written in English. Characteristics of each were then summarized and analyzed.</p><p><strong>Results: </strong>39 cases were included in our review - 27 due to the COVID-19 vaccine and 12 due to COVID-19 infection. Mean age of onset was similar, but mean time to onset was sooner in the vaccination group. Common treatments included systemic steroids, and almost all patients experienced complete recovery with the exception of a few patients in the COVID-19 infection cohort.</p><p><strong>Conclusion: </strong>While most cases are self-limiting and resolve with no long-term sequalae, the occurrence of more severe reactions appears to be associated with COVID-19 infection rather than with vaccination.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"114-123"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?","authors":"Michaela Houghton, Annwyne Houldsworth","doi":"10.1093/skinhd/vzaf022","DOIUrl":"10.1093/skinhd/vzaf022","url":null,"abstract":"<p><p>Oncolytic viruses (OVs) can destroy cancer cells without harming healthy cells. This review explores the mechanisms by which OVs operate and the methods of delivering them. Melanoma is a common type of skin cancer with increasing prevalence in the UK; therefore, finding effective strategies to combat the disease is paramount. To understand the potential of OVs in treating melanoma, different types of viruses will be reviewed. Talimogene laherparepvec (T-VEC) is the only OV to be approved for treating melanoma; this review aims to understand the efficacy of T-VEC as a monotherapy and combined with other treatments. There is substantial evidence to support the use of OVs in treating melanoma by synthesizing the current perspectives of their use where they proved to be effective in clinical trials, as monotherapies and in combination with other treatments, as well as exciting innovative ventures using novel virus species. Gaps are also highlighted in the research, such as determining the influence that cancer gene mutational status has on how the tumour cells react to treatment, a concept that should also be considered in future research.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"102-113"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-producing a randomized controlled trial on the frequency of bathing in eczema: description of a citizen science approach.","authors":"Arabella Baker, Natalie Bonsu, Laura Howells, Ingrid Muller, Eleanor J Mitchell, Fiona Cowdell, Firoza Davies, Mars Eddis-Finbow, Alan Montgomery, Devin Patel, Goldie Putrym, Matthew J Ridd, Miriam Santer, Amanda Roberts, Kim S Thomas","doi":"10.1093/skinhd/vzaf005","DOIUrl":"10.1093/skinhd/vzaf005","url":null,"abstract":"<p><strong>Background: </strong>Eczema is a prevalent, chronic, itchy skin condition that often persists into adulthood and significantly affects the quality of life of patients and their families. With no cure available at present, effective management is crucial. Although important patient priorities related to eczema self-management have been identified, they are rarely the focus of large, high-quality randomized controlled trials (RCTs).</p><p><strong>Objectives: </strong>To outline the methodology of using a citizen science approach to co-produce an online RCT on the frequency of bathing, to support the self-management of eczema.</p><p><strong>Methods: </strong>The co-production of the trial with patients living with eczema involved research prioritization, intervention development and trial design, all carried out through a series of online meetings and surveys.</p><p><strong>Results: </strong>Co-producing the trial took 9 months, consisting of 13 online meetings (5 to prioritize the topic, 4 to develop the intervention and 4 to design the trial), requiring 39 h of time commitment from members of the public (<i>n</i> = 12) with a total spending of £5440 on reimbursements. A prioritization survey (<i>n</i> = 120) identified the most popular research question as how often to bath/shower, receiving 49% of votes. Following an iterative refinement among the co-production group members, the trial research question was formulated. The intervention development survey (<i>n</i> = 169) established current bathing practices and interest in participating in the trial. Survey results informed the development of study materials and influenced decisions related to trial design. The finalized study materials included key information about the target behaviour (weekly bathing or daily bathing), frequently asked questions and common concerns. The trial design co-production group determined the eligibility criteria, defined the intervention and comparator, selected the outcome measures, determined the study duration and developed the recruitment strategy. The Eczema Bathing Study opened to recruitment on 29 January 2024 and over 50% of the target sample size of 390 have been recruited within the first 2 months.</p><p><strong>Conclusions: </strong>This paper provides a useful model for co-producing RCTs with members of the public. It describes the key stages of trial development (prioritization, intervention development, trial design) and contains information on the time and resources required to design trials using this approach.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"130-139"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of refractory alopecia areata successfully treated by combining delgocitinib ointment with excimer laser.","authors":"Yukito Kakeji, Toshiaki Kogame, Yosuke Yagi, Naotomo Kambe, Kenji Kabashima","doi":"10.1093/skinhd/vzaf013","DOIUrl":"10.1093/skinhd/vzaf013","url":null,"abstract":"<p><p>Alopecia areata (AA) is an autoimmune disease that causes recurrent hair loss. No treatment has been effective in the long term because of the unstable efficacy and possible side effects. AA is primarily driven by Th1-type inflammation, centred around CD8⁺ T cells and interferon-γ (IFN-γ). Recent studies have revealed that the Janus kinase (JAK) family is also involved in the pathogenesis of AA, leading to JAK inhibitors emerging as a treatment for AA. We present a case of a 39-year-old Japanese woman with severe AA who exhibited a Severity of Alopecia Tool (SALT) score 80 accompanied by atopic dermatitis (AD). Despite conventional treatments, the condition worsened from a SALT score of 80 to 100. We subsequently attempted treatment with an excimer laser (EL), but no hair regrowth was observed. However, the introduction of 0.5% delgocitinib ointment in combination with EL led to complete hair regrowth beginning 2 months later, with complete remission achieved after 1 year. This case highlights the potential efficacy of combining delgocitinib ointment with EL in treating severe AA, particularly in patients with AD. The findings suggest that this combination therapy may provide a safer and more effective alternative to oral JAK inhibitors. Nevertheless, further studies are needed to elucidate the underlying mechanisms and fully evaluate the therapeutic synergy.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"154-157"},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrophoderma vermiculatum (AV) and ipsilateral cataract.","authors":"Wei Qiang Chng, Kenneth Kinwai Fong","doi":"10.1093/skinhd/vzaf027","DOIUrl":"10.1093/skinhd/vzaf027","url":null,"abstract":"<p><p>We report a young child who presented with atrophic reticulated depressions with ipsilateral cataracts, suggesting that this could represent a distinct and rare entity.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"166"},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirabrutinib-associated toxic epidermal necrolysis: a case report and review of the literature.","authors":"Noriko Ikegawa, Natsuko Saito-Sasaki, Yu Sawada","doi":"10.1093/skinhd/vzaf011","DOIUrl":"10.1093/skinhd/vzaf011","url":null,"abstract":"<p><p>Tirabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in recurrent or refractory diffuse large B-cell lymphoma (DLBCL). However, severe drug eruptions, including toxic epidermal necrolysis (TEN), have been reported. We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment. Severe drug eruptions linked to tirabrutinib are rare, with only three cases reported, including ours. Tirabrutinib's selective BTK inhibition may activate cytotoxic CD8⁺ T cells, contributing to Stevens-Johnson syndrome/TEN pathogenesis. Further studies are needed to clarify the mechanisms and develop better diagnostic approaches for BTK inhibitor-related drug eruptions.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"151-153"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itraconazole-associated purpuric drug eruption: a rare adverse effect of a commonly prescribed drug.","authors":"Mahesh Mathur, Sandhya Regmi, Sumit Paudel, Supriya Paudel, Nabita Bhattarai, Sambidha Karki","doi":"10.1093/skinhd/vzaf006","DOIUrl":"10.1093/skinhd/vzaf006","url":null,"abstract":"<p><p>Purpuric drug eruption (PDE) is a rare drug reaction characterized by purpuric macules, papules and confluent plaques predominantly on the lower extremities. The drugs reported to induce PDE are epidermal growth factor receptor inhibitors, ketoconazole, acetylsalicylic acid, penicillin, sulfonamides, indomethacin, lenalidomide, linezolid and vancomycin. Drug-induced thrombocytopenia, platelet dysfunction and direct toxic effects of the drug on the capillary wall leading to increased capillary fragility are the proposed aetiologies. There is only a single report of itraconazole-induced PDE in the literature to date. We herein present a case of 57-year-old woman with PDE due to itraconazole.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"148-150"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}